News | January 01, 2025
Sanofi acquires rights to develop and commercialize Aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Merck has also decided to end the favezelimab clinical development program
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Subscribe To Our Newsletter & Stay Updated
